|
Puerto Rico |
|
Diving Medicine Articles By Dr. E.D. Thalmann, DAN Assistant Medical Director
Note: The decongestant pseudoephedrine is a commonly used drug by scuba
divers, with mixed - though generally positive - reviews from sport divers,
technical divers and diving professionals alike.
DAN has received many inquiries for recreational divers who would like to
know whether it is safe to take pseudoephedrine during enriched-air nitrox (EAN)
diving. This inquiry is usually tied specifically to divers having read or heard
the recommendation by diving organizations that pseudoephedrine be avoided with
EAN.
It has been reported in dive publications and in EAN manuals that some drugs
are CNS [central nervous system] exciters that predispose divers to CNS
toxicity. The October 1995 American Academy of Underwater Scientists (AAUS)
workshop on enriched air has been cited as the source for some of this
information, including naming the decongestant pseudoephedrine HCL (found in
Sudafed™ and other decongestant products) as a CNS exciter.
Before answering the question of whether pseudoephedrine may predispose a
diver to oxygen toxicity during enriched-air diving and whether it is safe for
air diving, it is useful to look at the line of reasoning on which I based it.
The first question is: How was it determined that there is an association
between pseudoephedrine and CNS oxygen toxicity? (For a discussion of CNS oxygen
toxicity, see If You Dive Nitrox, You Should Know About OXTOX). First, I needed
to look at the American Association of Underwater Sciences (AAUS) workshop
proceedings referenced in the statement by the cerification organizations. So I
went to work.
After a few phone calls and emails, I discovered that no proceedings for that
workshop were ever published. The statement regarding pseudoephedrine was based
on an article in a technical diving training association's journal. In this
article, the author cites several incidents involving decongestants and diving
listed below. After each incident from the journal I have put my own comments in
italics.
What can be made of these incidents? Starting with pharmacology,
pseudoephedrine is a sympathomimetic (has effects similar to substances found in
the sympathetic nervous system) whose major effect is to cause vasoconstriction
in the lining of the nose and sinuses, thus reducing stuffiness and congestion.
It is considered a mild central nervous stimulant, and its usual side effects
are excitability, restlessness, dizziness, weakness and insomnia. Large doses
(greater than those recommended) may induce several undesirable side effects
including cardiovascular collapse and convulsions.
Sounds like pretty ominous stuff could occur from simply taking a drug to
relieve a stuffy nose, doesn't it? Well, first of all, drug manufacturers are
required to report any and all side effects that may be associated with a drug,
no matter how rare. Even aspirin in high doses can cause cardiovascular collapse
and convulsions.
The reality is that adverse reactions to pseudoephedrine are rare in healthy
people when it is used as directed. That is not to say that certain individuals
may have an idiosyncratic reaction to the drug and experience undesirable
reactions to a drug while most others do not. For this reason, one should never
use a drug for the first time just before diving and should make sure to use it
long enough to determine that no hypersensitivity to the drug exists.
What the author has presented in his article constitutes anecdotal evidence
that pseudoephedrine may be associated with some undesirable side effects when
taken before a dive. The issue, however, is this: Does this anecdotal evidence
point to a predisposition to oxygen toxicity from taking pseudoephedrine?
While we have some evidence of an association between pseudoephedrine and
these side effects, we really need to establish a cause-and-effect relationship.
The following five criteria are used to make this connection:
"Statistical association" means that there is statistical
evidence that symptoms that occur when pseudoephedrine is taken in association
with certain types of dives are not a random occurrence. Mount did not provide
enough information to establish a statistical association.
"Strength of association" means that very frequently, when
the drug is taken before a dive, some sort of untoward effect usually occurs
during or after the dive: that is, the incidence of effects when pseudoephedrine
is take in association with a dive is very high.
Conversely, if no pseudoephedrine is taken, similar types of dives almost
never produce side effects. Since we don't know how many individuals take
pseudoephedrine before diving with no effects, like those reported above, we
can't measure the incidence.
"Timing of association" means that the reported side effects
usually occur if the drug is taken before a dive, and not if it is taken
afterward. Since only incidents in which the drug was taken before the dive were
reported, we can't invoke this criteria.
"Consistency of response" means that the same effect is seen
when the drug is taken, although the incidence may be rare. There does not seem
to be any consistency in the symptoms reported above.
"Biological plausibility" means that there is some
identified mechanism by which the drug could cause an undesirable side effect.
In particular, we are interested in whether it may enhance susceptibility to
oxygen toxicity. Here, we do have some evidence. In 1962, none other than DAN's
Chief Executive Officer, Dr. Peter Bennett, while working as a research
physiologist at the Royal Navy Physiological Laboratory in England, published a
paper (Life Sciences; 12:721-727, 1962) testing the hypothesis that oxygen
toxicity and nitrogen narcosis were caused by similar mechanisms.
He found that in rats, sympathomimetics seemed to enhance oxygen toxicity.
Pseudoephedrine was not tested specifically, but it is a sympathomimetic, so we
might infer that it has a similar effect. In addition, our current understanding
of the mechanisms which produce oxygen convulsions would predict that
sympathomimetic drugs might enhance susceptibility to oxygen convulsions. It has
been shown that drugs which inhibit sympathetic stimulation seem to reduce the
likelihood of oxygen convulsions in animals. No human studies have ever been
done. Thus, at least a theoretical reason exists why pseudoephedrine should be
avoided while diving on high PO2 dives.
What's the bottom line? In normal, healthy divers breathing air,
occasional use of pseudoephedrine at the recommended dose is probably safe. This
presumes that the drug has been taken during periods when no diving has occurred
and that no undesirable reactions have occurred. However, one should avoid
chronic (daily) use when diving, and it seems reasonable to avoid the drug
entirely if diving while using oxygen-nitrogen mixes where the PO2 during a dive
might exceed 1.4 ata, the current recommended "safe" open-circuit
scuba limit.
Why the "long way around the barn" in reaching this conclusion?
It is simply to present some tools and a logical process by which one can decide
if anecdotal associations are due to an actual cause-and-effect relationship.
Next time you hear that someone has suffered an undesirable effect from
taking a drug or trying out some new dive gear, apply the five criteria given
above to decide for yourself whether a cause-and-effect relationship exists.
*The partial pressure of a gas is the measure of the number of molecules in a
given volume. If a gas has only one component - 100 percent oxygen, for example
- the partial pressure and the pressure are the same. With a gas mix, the
partial pressure is the gas fraction times the total pressure. The physiological
effects of a gas are due mainly to its partial pressure, no matter what the
total pressure is.
(c) November/December 1999 Alert Diver |